Free Trial

This company has been marked as potentially delisted and may not be actively trading.

NASDAQ:PDLI

PDL BioPharma (PDLI) Stock Price, News & Analysis

PDL BioPharma logo

About PDL BioPharma Stock (NASDAQ:PDLI)

Advanced Chart

Key Stats

Today's Range
$2.47
$2.47
50-Day Range
$2.47
$2.47
52-Week Range
$2.09
$3.86
Volume
N/A
Average Volume
N/A
Market Capitalization
N/A
P/E Ratio
N/A
Dividend Yield
N/A
Price Target
N/A
Consensus Rating
N/A

Company Overview

Receive PDLI Stock News and Ratings via Email

Sign-up to receive the latest news and ratings for PDL BioPharma and its competitors with MarketBeat's FREE daily newsletter.

PDLI Stock News Headlines

GT Biopharma Inc GTBP
Health Winners & Losers: Maxygen
Presidential Bombshell: $150T Resource to Be Released as soon as this Summer?
Something extraordinary is happening in Washington. For the first time in over a century, a sitting President could release a national treasure that's been tied up in red tape, for generations. I'm talking about a $150 trillion American asset that's scattered across all 50 states. While the mainstream media focuses on political theater, this story is quietly developing behind closed doors.
PDLI Historical Data
ABVC - ABVC BioPharma, Inc.
RDHL - RedHill Biopharma Ltd.
LABP
See More Headlines

PDLI Stock Analysis - Frequently Asked Questions

PDL BioPharma, Inc. (NASDAQ:PDLI) released its quarterly earnings data on Thursday, August, 6th. The biotechnology company reported ($0.43) earnings per share for the quarter, missing analysts' consensus estimates of $0.10 by $0.53. The biotechnology company had revenue of $5.21 million for the quarter.

Based on aggregate information from My MarketBeat watchlists, some other companies that PDL BioPharma investors own include AT&T (T), OPKO Health (OPK), Advanced Micro Devices (AMD), Canopy Growth (CGC), Novavax (NVAX), Pfizer (PFE) and Sorrento Therapeutics (SRNE).

Company Calendar

Last Earnings
8/06/2020
Today
7/04/2025
Fiscal Year End
12/31/2025

Industry, Sector and Symbol

Stock Exchange
NASDAQ
Sector
Medical
Industry
MED - BIOMED/GENE
Sub-Industry
Biotechnology
Current Symbol
NASDAQ:PDLI
Employees
109
Year Founded
N/A

Profitability

Trailing P/E Ratio
13.00
Forward P/E Ratio
N/A
P/E Growth
N/A
Pretax Margin
N/A

Debt

Sales & Book Value

Annual Sales
N/A
Price / Cash Flow
N/A
Price / Book
N/A

Miscellaneous

Free Float
N/A
Optionable
Optionable
Beta
N/A
20 Stocks to Sell Now Cover

Today, we are inviting you to take a free peek at our proprietary, exclusive, and up-to-the-minute list of 20 stocks that Wall Street's top analysts hate.

Many of these appear to have good fundamentals and might seem like okay investments, but something is wrong. Analysts smell something seriously rotten about these companies. These are true "Strong Sell" stocks.

Get This Free Report

This page (NASDAQ:PDLI) was last updated on 7/4/2025 by MarketBeat.com Staff
From Our Partners